|
|
 |
|
Viewing report
|
|
|
|
Wyeth: SWOT Analysis & Company Profile
Business Review, March 2010, Pages: 29
Synopsis
Business Review’s Wyethcontains a company overview, key facts, locations and subsidiaries, news and events as well as a SWOT analysis of the company.
Summary
This SWOT Analysis company profile is a crucial resource for industry executives and anyone looking to quickly understand the key information concerning Wyeth business.
Business Review’s “Wyeth: SWOT Analysis & Company Profile” reports utilize a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format.
Business Review strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report.
Scope
- Examines and identifies key information and issues about (Wyeth) for business intelligence requirements.
- Studies and presents Wyeth's strengths, weaknesses, opportunities (growth potential) and threats (competition). Strategic and operational business information is objectively reported.
- The profile contains business operations, the company history, major products and services, prospects, key competitors, key employees, locations and subsidiaries.
Reasons To Buy
- Quickly enhance your understanding of the company.
- Obtain details and analysis of the market and competitors as well as internal and external factors which could impact the industry.
- Increase business/sales activities by understanding your competitors’ businesses better.
- Recognize potential partnerships and suppliers.
- Obtain yearly profitability figures.
Key Highlights
Wyeth is engaged in developing and providing pharmaceuticals and healthcare products for consumers and animals. Its product line includes treatments across a wide range of therapeutic areas. Wyeth is focused on the research and development of products for solving the world's most critical health problems. It also develops products for hematologic and solid organ malignancies, infectious diseases and preventative vaccines, and treatments in women's health including osteoporosis and vasomotor symptoms of menopause, etc. The company is headquartered at Madison, New Jersey, the US. In January 2009, Wyeth entered into a strategic alliance with Santaris Pharma to develop RNA-based Medicines. In the same month, Wyeth also entered into a merger agreement with Pfizer, under which Pfizer will acquire Wyeth. In June 2009, Wyeth Pharmaceuticals, a division of Wyeth, and Catalyst Biosciences, Inc. entered into an exclusive worldwide collaboration to discover, develop and commercialize Factor VIIa products to treat hemophilia and other bleeding conditions. In September 2009, the company provided data from five-year vertebral fracture prevention study with Bazedoxifene, which demonstrated significant reduction versus placebo in new vertebral fractures if treated with bazedoxifene 20mg.
|
|
|
|
